HC Wainwright & Co. Maintains Buy on Cardiff Oncology, Raises Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has maintained a Buy rating on Cardiff Oncology (NASDAQ:CRDF) and increased the price target from $12 to $14.
March 06, 2024 | 11:49 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cardiff Oncology's Buy rating is maintained by HC Wainwright & Co., with the price target raised from $12 to $14.
The maintenance of a Buy rating combined with an increased price target typically signals a positive outlook on the stock from the analyst's perspective. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100